Download presentation
Presentation is loading. Please wait.
Published byJózef Kołodziejczyk Modified over 6 years ago
1
Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy
2
Learning Objectives
3
Patient Case MB
4
Elotuzumab Background
5
ELOQUENT-2 Study Design Len/Dex ± Elotuzumab
6
ELOQUENT-2 Efficacy
7
ELOQUENT-2 Safety
8
Patient Case JP
9
Ixazomib Drug Interactions
10
Ixazomib
11
TOURMALINE-MM1 Ixazomib + Len/Dex vs Placebo + Len/Dex
12
TOURMALINE-MM1 Efficacy
13
TOURMALINE-MM1 Toxicity
14
Ixazomib Pharmacist Perspective
15
Other Ixazomib Combinations
16
Patient Case (cont) JP
17
Daratumumab
18
Daratumumab Combination Therapy
19
Current and Future Place in Therapy
20
Therapies in Development Antibodies
21
Pembrolizumab + Pom/Dex
22
Pembrolizumab + Pom/Dex Safety and Tolerability
23
Therapies in Development
24
Questions and Answers
25
Abbreviations
26
Abbreviations (cont)
27
Abbreviations (cont)
28
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.